The field is transitioning from single-pathway inhibition toward rational, biomarker-guided combination strategies aimed at disabling adaptive survival networks rather than KRAS signaling alone. Future success of PDAC pharmacotherapy will depend on improved patient selection, validation of predictive biomarkers, and innovative clinical trial designs capable of balancing efficacy with the toxicity of multi-agent regimens.
Pokora et al. (Thu,) studied this question.